K-Ras G12C-IN-3

• CAT Number: I002114
• CAS Number: 1629268-19-4
• Molecular Formula: C21H19Cl3N2O3
• Molecular Weight: 453.74
• Purity: ≥95%
• Synonyms: 1-(4-(2/’,5/’,6-trichloro-4-methoxy-[1,1/’-biphenyl]-3-carbonyl)piperazin-1-yl)prop-2-en-1-one
• Target: MAPK/ERK Pathway
• Solubility: DMSO: ≥ 40 mg/mL
• Storage: Store at -20°C
• IUPAC Name: 1-[4-[4-chloro-5-(2,5-dichlorophenyl)-2-methoxybenzoyl]piperazin-1-yl]prop-2-en-1-one
• InChI: InChI=1S/C21H19Cl3N2O3/c1-3-20(27)25-6-8-26(9-7-25)21(28)16-11-15(18(24)12-19(16)29-2)14-10-13(22)4-5-17(14)23/h3-5,10-12H,1,6-9H2,2H3
• InChIKey: RPBHAPLCWWQJAK-UHFFFAOYSA-N
• SMILES: COC1=C(C=C(C(=C1)Cl)C2=C(C=CC(=C2)Cl)Cl)C(=O)N3CCN(CC3)C(=O)C=C

K-Ras G12C-IN-3（Cat No.:I002114）is a small molecule inhibitor designed to target the K-Ras G12C mutation, a common oncogenic driver in various cancers, including non-small cell lung cancer (NSCLC), colorectal cancer, and pancreatic cancer. The G12C mutation leads to constitutive activation of Ras signaling, promoting tumor growth. K-Ras G12C-IN-3 works by selectively binding to the cysteine residue at position 12 of the mutated K-Ras protein, locking it in an inactive state and preventing downstream signaling. This targeted therapy has shown promise in preclinical studies for treating K-Ras G12C-mutant cancers.